Open Access
EPJ Nonlinear Biomed Phys
Volume 2, Number 1, December 2014
Article Number 13
Number of page(s) 40
Published online 05 November 2014
  1. World Health Organization: WHO global report: Noncommunicable diseases country profiles 2011. Date: September, 2011 ISBN: 9789241502283 [] [Google Scholar]
  2. KEGG PATHWAY Database - Metabolism[\#metabolism] [Google Scholar]
  3. KEGG PATHWAY Database - Cellular Processes[\#cellular] [Google Scholar]
  4. KEGG PATHWAY Database - Human Diseases[\#disease] [Google Scholar]
  5. Rowinsky EK, Wright M, Monsarrat B, Lesser GJ, Donehower RC: Taxol: pharmacology, metabolism and clinical implications. Cancer Surv1993, 17:283–304. [Google Scholar]
  6. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, Pinedo HM, Beijnen JH: Taxanes: a new class of antitumor agents. Cancer Invest1995, 13:381–404. [Google Scholar]
  7. Kim TY, Kim DW, Chung JY, Shin SG, Kim SC, Heo DS, Kim NK, Bang YJ: Phase i and pharmacokinetic study of genexol-pm, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res2004, 10:3708. [Google Scholar]
  8. Robinson DM, Keating GM: Albumin-bound paclitaxel in metastatic breast cancer drugs. Drugs2006, 66:941. [Google Scholar]
  9. Mori T, Kinoshita Y, Watanabe A, Yamaguchi T, Hosokawa K, Honjo K: Retention of paclitaxel in cancer cells for 1 week in vivo and in vitro. Cancer Chemother Pharmacol2006, 58:665–675. [Google Scholar]
  10. Henningsson A, Karlsson MO, Vigano L, Gianni L, Verweij J, Sparreboom AA: Mechanism-based pharmacokinetic model for paclitaxel. J Clin Oncol2001, 19:4065. [Google Scholar]
  11. Brana MF, Cacho M, Gradillas A, Pascual-Teresa B, Ramos A: Intercalators as anticancer drugs. Curr Pharm Des2001, 7:1745–1780. [Google Scholar]
  12. Hickman JA, Beere HM, Wood AC, Waters CM, Parmar R: Mechanisms of cytotoxicity caused by antitumor drugs, 6th international congress of toxicology: toxicology from discovery and experimentation to the human perspective. Toxicol Lett1992, 64–65:553–561. [Google Scholar]
  13. Kiechle FL, Zhang XB: Apoptosis: biochemical aspects and clinical implications. Clinica Chimica Acta2002, 326:27–45. [Google Scholar]
  14. Carter SK, Comis RL: Integration of chemotherapy into a combined modality approach for cancer treatment for pancreatic adenocarcinoma. Cancer Treat Rev1975, 2:193–214. [Google Scholar]
  15. Lenaz L, Page JA: Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev1975, 3:111–120. [Google Scholar]
  16. Locker GY, Doroshow JH, Myers CE: Glutathione peroxidase - its role in adriamycin cardiotoxicity. In Proceedings of the American Association for Cancer Research: Volume 18. Philadelphia: American Association for Cancer Research; 1977:87. [Google Scholar]
  17. Wallace KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol2003, 93:105–115. [Google Scholar]
  18. Kurabayashi M, Jeyaseelan R, Kedes L: Doxorubicin represses the function of the myogenic helix-loop-helix transcription factor myod - involvement of id gene induction. J Biol Chem1994, 269:6031–6039. [Google Scholar]
  19. Boucek RJ, Miracle A, Anderson M, Engelman R, Atkinson J, Dodd DA: Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol1999, 31:1435–1446. [Google Scholar]
  20. Gibaldi M, Perrier D: Pharmacokinetics. 2nd edition, New York: M. Dekker; 1982. [Google Scholar]
  21. Macheras P: A fractal approach to heterogeneous drug distribution: calcium pharmacokinetics. Pharm Res1996, 13:663–670. [Google Scholar]
  22. Fuite J, Marsh RE, Tuszynski JA: Fractal pharmacokinetics of the drug mibefradil in the liver. Phys Rev E2002, 66:021904. [Google Scholar]
  23. Marsh RE, Tuszynski JA, Sawyer MB, Vos KJE: Emergence of power laws in the pharmacokientics of paclitaxel due to competing saturable processes. J Pharmacy Pharmaceutical Sci2008, 11:77–96. [Google Scholar]
  24. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, Simmerling C: Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins2006, 65:712–25. [Google Scholar]
  25. Yano JK, Wester MR, Schoch GA, Griffin KJ, Stout CD, Johnson EF: The structure of human microsomal cytochrome p450 3a4 determined by x-ray crystallography to 2.05-a resolution. J Biol Chem2004, 279:38091–38094. [Google Scholar]
  26. Bennet MJ, Barakat K, Huzil JT, Tuszynski JA, Schriemer DC: Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol2010, 17:725–734. [Google Scholar]
  27. Gianni L, Vigano L, Locatelli A, Capri G, Giani A, Tarenzi E, Bonadonna G: Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol1997, 15:1906–1915. [Google Scholar]
  28. Moreira A, Lobato R, Morais J, Silva S, Ribeiro J, Figueira A, Vale D, Sousa C, Araujo F, Fernandes A, Oliveira J, Passos-Coelho JL: Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemotherapy Pharmacol2001, 48:333–337. [Google Scholar]
  29. Benjamin RS, Riggs CE, Bachur NR: Influence of the interval between the administration of doxorubicin and paclitaxel on the pharmacokinetics of these drugs in patients with locally advanced breast cancer. Cancer Chemotherapy Pharmacol2001, 48:333–337. [Google Scholar]
  30. Andersen A, Holte H, Slordal L: Pharmacokinetics and metabolism of doxorubicin after short-term infusions in lymphoma patients. Cancer Chemotherapy Pharmacol1999, 44:422–426. [Google Scholar]
  31. Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers CE: Plasma pharmacokinetics of adriamycin and adriamycinol: Implications for the design of in vitro experiments and treatment protocols. Cancer Res1983, 43:3417–3421. [Google Scholar]
  32. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol1995, 13:180–190. [Google Scholar]
  33. Ohtsu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N: Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res1995, 1:599–606. [Google Scholar]
  34. Ekroos M, Sjogren T: Structural basis for ligand promiscuity in cytochrome p450 3a4. Proc Natl Acad Sci U S A2006, 103:13682–13687. [Google Scholar]
  35. Boucek RJ, Olson RD, Brenner DE, Ogunbunmi EM, Inui M, Fleischer S: The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions. J Biol Chem1987, 262:15851–15856. [Google Scholar]
  36. Hornberg JJ, Bruggeman FJ, Westerhoff HV, Lankelma J: Cancer: a systems biology disease. Biosystems2006, 83:81–90. [Google Scholar]
  37. Mross K, Niemann B, Massing U, Drevs J, Unger C, Bhamra R, Swenson C: Pharmacokinetics of liposomal doxorubicin (tlc-d99; myocet) in patients with solid tumors: an open-label, single-dose study. Cancer Chemother Pharmacol2004, 54:514–524. [Google Scholar]
  38. Di Fronzo G, Lenaz L, Bonadonna G: Distribution and excretion of adriamycin in man. Biomedicine1973, 19:169–171. [Google Scholar]
  39. Jacquet JM, Bressolle F, Galtier M, Bourrier M, Donadio D, Jourdan J, Rossi JF: Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters. Cancer Chemother Pharmacol1990, 27:219–225. [Google Scholar]
  40. Bressolle F, Ray P, Jacquet JM, Bres J, Galitier M, Donadio D, Jourdan J, Rossi JF: Bayesian estimation of doxorubicin pharmacokinetic parameters. Cancer Chemother Pharmacol1991, 29:53–60. [Google Scholar]
  41. Eksborg S, Strandler HS, Edsmyr F, Naslund I, Tahvanainen P: Pharmacokinetic study of iv infusions of adriamycin. Eur J Pharmacol1985, 28:205–212. [Google Scholar]
  42. Chan KK, Chlebowski RT, Tong M, Chen HSG, Gross JF, Bateman JR: Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res1980, 40:1263–1268. [Google Scholar]
  43. Monsarrat B, Chatelut E, Royer I, Alvineirie P, Dubois J, Dezeuse A, Roche H, Cros S, Wright M, Canal P: Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome p450 3a4. Drug Metab Dispos1998, 26:229–233. [Google Scholar]
  44. Mross K, Hollander N, Hauns B, Schumacher M, Maier-Lenz H: The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol2000, 45:463–470. [Google Scholar]
  45. Brown T, Havlin K, Weiss G, Cagnola J, Koeller J, Kuhn J, Rizzo J, Craig J, Phillips J, Von Hoff D: A phase 1 trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol1991, 9:1261–1267. [Google Scholar]
  46. Longnecker SM, Donehower RC, Cates AE, Chen TL, Brundrett RB, Grochow LB, Ettinger DS, Colvin M: High-performance liquid chromatography assay for taxol in human plasma and urine and pharmacokinetics in a phase i trial. Cancer Treat Rep1987, 71:53–59. [Google Scholar]
  47. Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J: Randomized phase ii study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J Clin Oncol1999, 17:3038–3047. [Google Scholar]
  48. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res1987, 47:2486–2493. [Google Scholar]
  49. Maier-Lenz H, Hauns B, Haering B, Koetting J, Mross K, Unger C, Bauknecht T, duBois A, Meerpohl HG, Hollaender N, Diergarten K: Phase i study of paclitaxel administration as a 1-hr infusion: Toxicity and pharmacokinetics. Semin Oncol1997, 24:19–161919. [Google Scholar]